FDA Video: Velcade and Hepatic Impairment

FDA is notifying healthcare professionals that patients with moderate to severe hepatic impairment who are beginning therapy with Velcade (bortezomib) should be started at reduced doses and closely monitored for toxicity. This recommendation does not apply to those with mild hepatic impairment. Velcade is used to treat patients with multiple myeloma and those with mantle cell lymphoma who have received at least one prior therapy.